Viamet Pharmaceuticals Initiates Phase 1 Clinical Program with Novel Antifungal Agent VT-1161  
9/14/2011 10:34:41 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology. VT-1161 has been shown in preclinical studies to potently inhibit a wide range of fungal pathogens causing human disease, while maintaining a very significant safety margin. The initial Phase 1 study, a single-ascending dose trial in healthy volunteers, is currently being conducted in the United States.